Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate+emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 3, 2010, Pages 556-561

  Valantin, M A ^a,b   Bittar, R ^a   de Truchis, P ^c   Bollens, D ^d   Slama, L ^e   Giral, P ^a   Bonnefont Rousselot, D ^a,f   Petour P ^g   Aubron Olivier, C ^g   Costagliola, D ^a,b   Katlama, C ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSERM   (France)

^c RAYMOND POINCARÉ HOSPITAL   (France)

^d HÔPITAL SAINT ANTOINE   (France)

^e HÔPITAL TENON   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g Gilead Sciences   (France)

Author keywords

Antiretroviral drugs; HIV infection; Lipid abnormalities

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL;

ADULT; ANXIETY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INTESTINE OBSTRUCTION; ISCHIALGIA; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TABLET; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD;

ADENINE; ADULT; ANTI-HIV AGENTS; CHOLESTEROL, LDL; DEOXYCYTIDINE; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NUCLEOSIDES; PHOSPHONIC ACIDS; TRIGLYCERIDES;

EID: 77950318555     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp462     Document Type: Article

References (23)

1. Savès M, Chêne G, Ducimetière P et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 2003; 37: 292-8.
2. El-Sadr WM, Lundgren JD, Neaton JD et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 2283-96.
3. Mary-Krause M, Cotte L, Simon A et al. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17: 2479-86.
4. Bozzette SA, Ake CF, Tam HK et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348: 702-10.
5. Friis-Møller N, Reiss P, Sabin CA et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 1723-35.
6. Sabin CA, Worm SW, Weber R et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371: 1417-26.
7. Costagliola D. The current debate on abacavir; risks and relationship between HIV viremia and cardiovascular events. In: Abstracts of the Fifth IAS conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, July 2009. Abstract MOAB201. http://www.ias2009.org/pag/PSession.aspx?s=2419 (20 October 2009, date last accessed).
8. Clumeck N, Pozniak A, Raffi F et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med 2008; 9: 65-71.
9. Schambelan M, Benson CA, Carr A et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 2002; 31: 257-75.
10. Yeni P. Prise en charge médicale des personnes infectées par le VIH. Recommandations du groupe d'experts. Flammarion Médecine-Sciences, 2006. http://www.sante.gouv.fr/htm/actu/yeni_sida/rapport_experts_2006.pdf (20 October 2009, date last accessed).
11. Hammer SM, Eron JJ Jr, Reiss P et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300: 555-70.
12. Lundgren JD, Battegay M, Behrens G et al. European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med 2008; 9: 72-81.
13. Moyle GJ, Sabin CA, Cartledge J et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006; 20: 2043-50.
14. Domingo P, Labarga P, Palacios R et al. Improvement of dyslipidemia in patients switching from stavudine to tenofovir: preliminary results. AIDS 2004; 18: 1475-8.
15. Llibre JM, Domingo P, Palacios R et al. Sustained improvement of dyslipidemia in HAART-treated patients replacing stavudine with tenofovir. AIDS 2006; 20: 1407-14.
16. Milinkovic A, Martinez E, López S et al. The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients. Antivir Ther 2007; 12: 407-15.
17. Madruga JR, Cassetti I, Suleiman JM et al. The safety and efficacy of switching stavudine to tenofovir DF in combination with lamivudine and efavirenz in HIV-1-infected patients: three-year follow-up after switching therapy. HIV Clin Trials 2007; 8: 381-90.
18. Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem 1982; 28: 2077-80.
19. Allain CC, Poon LS, Chan CSG et al. Enzymatic determination of total serum cholesterol. Clin Chem 1974; 20: 470-5.
20. Egloff M, Leglise D, Duvillard L et al. Multicenter evaluation on different analysers of three methods for direct HDL-cholesterol assays. Ann Biol Clin 1999; 57: 561-72.
21. Bayer P, Veinberg F, Couderc C et al. Multicenter evaluation of four homogenous LDL-cholesterol assays. Ann Biol Clin 2005; 63: 27-41.
22. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
23. Riddler SA, Li X, Otvos J et al. Antiretroviral therapy is associated with an atherogenic lipoprotein phenotype among HIV-1-infected men in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr 2008; 48: 281-8.